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Abstract: Depression is a disabling condition resulting in significant impairment in social 
  functioning, involving the patient’s family, friends, work colleagues, and society at large. 
Although both psychologic and pharmacologic treatments generally improve many depressive 
symptoms, they do not always result in significant improvement in social functioning. The 
importance of recovery of social functioning in depressed patients is now widely appreciated, 
and studies are beginning to include it in evaluations of therapeutic efficacy. Among the   various 
social adjustment evaluation rating scales, the Social Adaptation Self-Evaluation Scale, a social 
motivation and behavior scale, has been found to be simple to use and sensitive to change. 
Using this scale, the selective norepinephrine reuptake inhibitor, reboxetine, has been shown 
to be significantly more effective in improving social functioning than the selective serotonin 
reuptake inhibitor, fluoxetine. These findings are consistent with the notion that improvement 
in social adaptation involves functions depending primarily on noradrenergic neurotransmission. 
This hypothesis suggests that the serotonin and norepinephrine reuptake inhibitors, venlafaxine, 
duloxetine, and milnacipran, could be particularly helpful in improving social functioning. 
Preliminary studies with the serotonin and norepinephrine reuptake inhibitors suggest that they 
significantly improve social functioning. Comparative studies with selective serotonin reuptake 
inhibitors on the effects on social functioning should be encouraged.
Keywords: Social Adaptation Self-Evaluation Scale, social functioning, depression, serotonin 
and norepinephrine reuptake inhibitors, noradrenergic neurotransmission
Introduction
The importance of social relationships in clinical psychiatry is well recognized.1 
Social functioning can be defined as the interaction of an individual with his/her 
environment and the ability to fulfill his/her role within it. An individual functions 
daily within several environments, ie, work, social and leisure, marital, parental, 
within the extended family,2 as well as with virtual networks. The major impact of 
depression on social   functioning and the consequences of impaired social   functioning 
on the global well-being of depressed patients has been well established.3–7 Social 
functioning is possibly one of the most important factors affecting the quality of life 
in depressed patients, although this has not yet been systematically investigated. For 
workers, depression has a profound effect on workplace functioning. Individuals with 
major depression have high rates of absenteeism and of presenteeism, a term used to 
describe the lost productivity a worker experiences when he is able to attend work 
but is not performing optimally.8
Impairment of social functioning may be substantial and long-lasting. The severity of 
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(those suffering simultaneously from dysthymia and major 
depression), for example, have been found to be significantly 
more impaired in overall social functioning than those with 
dysthymia or major depressive episodes alone.6 The main 
differences were in relationships with extended family and 
in social and leisure pursuits.6 The social dysfunction seen 
in patients with dysthymia is at least as severe as in patients 
with major depression.6 There is evidence that poor social 
support, maladjustment in social and leisure activities, and 
poor quality of relationships with extended family are strong 
predictors of recurrence of a major depressive episode.9 The 
protective effect of social contacts is undisputable, and has 
even been shown in a rodent model of depression.10
The difference between social functioning (or social 
adaptation) and social support needs to be clarified. Social 
adaptation is the ability of each person to “adapt” his/her 
behavior to make it appropriate to the social environment in 
which he/she finds his/herself. In contrast, “social support” 
refers to people who are emotionally close to the individual 
and who provide “understanding, encouragement and general 
positive feedback”. A depressive episode will not, at least in 
the early stages, alter the social support network of a patient. 
It does, however, profoundly alter his/her “social adaptation”, 
making him/her less socially acceptable. In the long term, 
this is likely to have a negative impact on the social support 
network of the patient. Lack of social support has been well 
established as a risk factor for depression.11–13
Full recovery from depression requires not only the reso-
lution of depressive symptoms, but also an improvement in 
the interaction of the individual with his/her environment.3,4,6 
Enhancement of social functioning or adaptation should 
thus be considered a therapeutic goal in the management of 
depression and, as such, should legitimately influence the 
choice of antidepressant therapy.5
This review explores the mechanisms underlying social 
dysfunction in depression, evaluation of its severity, and the 
effect of antidepressants on social functioning. Recent data 
for the serotonin and norepinephrine reuptake inhibitors 
(SNRIs) are reviewed in detail.
Mechanisms underlying social 
dysfunction in depressed patients
Human behavior is complex and rarely, if ever, the result of 
the action of a single neurotransmitter. However, it is possible, 
to define certain functions that are related more specifically 
to serotonergic, noradrenergic, or dopaminergic neurotrans-
mission. Noradrenergic neurotransmission is thought to be 
essential to sustain or enhance vigilance, motivation, and 
self-perception, whereas serotonin (5-hydroxytryptamine, 
5-HT) affects impulsivity and irritability, while dopamine 
(DA) is important in the regulation of drive.14,15
Widespread disturbances of monoamine neurotransmis-
sion occur in depression, and they are probably fundamental 
to its pathophysiology.16,17 More specifically, a deficiency in 
5-HT, norepinephrine (NE), and possibly DA neurotransmis-
sion has been suggested in depression.18–20 A relationship 
exists between the different neurotransmitter deficits and 
the symptoms of major depressive disorder21 (Figure 1). 
Agitation, loss of appetite, decreased libido, suicidal ideation, 
aggressive behavior (verbal or physical), and irritability are 
symptoms related principally to the dysfunction of seroton-
ergic neurotransmission.21,22 Decreased concentration, mental 
and physical slowing, loss of energy, lassitude, tiredness, and 
reduced self-care (hygiene) are symptoms related principally 
to reduced noradrenergic activity.21,22 Depressed mood, loss of 
interest or pleasure, sleep disturbances, feeling of worthless-
ness, pessimism, and anxiety are symptoms related to changes 
in both 5-HT and NE neurotransmission.21,22
The negative effects of depression on social functioning 
can be grouped into three main areas, ie, perceptual, cogni-
tive, and performance. As shown in Figure 1, the symptoms 
of depression implicated in problems of social functioning 
(in underlined italics in Figure 1) are those resulting primarily 
from noradrenergic dysfunction.
The importance of noradrenergic neurotransmission in 
social functioning is supported by studies using the specific 
NE reuptake inhibitor, reboxetine, in healthy volunteers. 
The effects of reboxetine have been studied using a stranger-
dyadic social interaction paradigm and cooperative game 
situations.23–25 Reboxetine was found to increase cooperative 
social behavior and social drive in healthy volunteers. 
In contrast, the selective serotonin reuptake inhibitor (SSRI), 
citalopram, had less effect on cooperative behavior.23 Two 
weeks’ enhancement of noradrenergic transmission induced 
by reboxetine made healthy volunteers more self-confident 
and assertive.25
Methods for assessing  
social adaptation
In the DSM-IV (Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition) diagnostic criteria for major depres-
sion, the item “lack of interests” only partially covers the 
concept of decreased social ability. However, in addition 
to the simple presence of certain symptoms, the DSM-IV 
requires that symptoms should cause significant distress or 
impairment in social, occupational, or other important areas Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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of functioning.26 Increasingly, the enhancement of social 
functioning is considered to be an important therapeutic 
  target in the treatment of depression.15,26,27 The   measurement 
of social adaptation should thus be an important part of 
  assessment of the outcome of depression. A number of instru-
ments have been developed to measure social functioning, 
each with its advantages and disadvantages.28
Although several self- or clinician-evaluated social 
adjustment scales are available, they are frequently complex 
and time-consuming, and their conceptual background is 
often poorly defined.29–31 The three most frequently used 
instruments for measuring social functioning are the 36-item 
Short-Form Health Survey,32 the Social Adjustment Scale 
Self-Report,33 and the more recently developed Social 
Adaptation Self-Evaluation Scale (SASS).29 It has been 
suggested28 that the SASS might be the most appropriate for 
studies exploring hypotheses about mechanisms involved in 
social dysfunction.
SASS instrument
The 21-item SASS was developed with two requirements, ie, 
simplicity of use and clear measurement of social behavior. 
It has been validated in a large sample of over 3000 people 
in the general population and in 496 depressed patients.26,27 
The SASS explores social functioning in the areas of work, 
leisure, family and extrafamily relationships, global social 
attitude, and self-perception vis à vis the environment. The 
21 items (Table 1) are scored from 0 to 3, (3 being maximal 
adjustment). Questions 1 and 2 are mutually exclusive, so 
that 20 questions are scored giving a total score range of 
0 to 60. Normal scores are in the range 35–52.29 The test 
takes 5–10 minutes to complete.
Agitation
Loss of appetite
Decreased libido
Suicidal ideation
Aggressive behavior
(oral or physical)
Irritability
Depressed mood
Loss of interest  or pleasure
Insomnia or hypersomnia
Feeling of worthlessness
Pessimism
Anxiety
Decreased
concentration
Retardation
Loss of energy
Lassitude
Tiredness
Reduced self-care
(hygiene)
Serotonergic
Noradrenergic
Figure 1 Influence of serotonergic and noradrenergic neurotransmission on the symptoms of depression. Symptoms in underlined italics are those that are directly related 
to social adaptation. Adapted from Nutt.21
Table 1 Social Adaptation Self-evaluation Scale questionnaire
21 questions exploring patient motivation and behavior25
1. Job interest
2. Home work interest
3. work enjoyment
4. interest in hobbies
5. Quality of spare time
6. Family seeking behavior
7. Family relationship quality
8. Gregariousness
9. Relationship seeking behavior
10. external relationship quality
11. external relationship appreciation
12. Social attractiveness
13. Social compliance
14. Community involvement
15. Social inquisitiveness
16. intellectual interest
17. Communication difficulties
18. Rejection sensitivity
19. vainness
20. Difficulties in coping with resources
21. Control of surroundingsNeuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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As discussed above, major depressive episodes have 
an extensive impact on work and family functioning, and 
thus antidepressant treatment would be expected to lead to 
improved social functioning. The first comparative study to 
use the SASS to evaluate the effects of antidepressant treat-
ment on social functioning was a randomized, double-blind, 
placebo-controlled, eight-week study comparing the selective 
NE reuptake inhibitor, reboxetine (8 mg/day) with the SSRI, 
fluoxetine (20 mg/day).34,35 At the end of the study, the mean 
SASS total score was significantly higher (P , 0.05) in both 
the reboxetine (n = 103) and fluoxetine (n = 100) groups 
compared with placebo (n = 99) group. The SASS total score 
in the reboxetine group, however, was significantly higher 
(P , 0.05) than in the fluoxetine group. Improvement from 
baseline in the three groups was reboxetine 41%, fluoxetine 
31%, and placebo 14%. Correlation analysis showed that 
19 out of 20 items of the SASS discriminated reboxetine 
from placebo, while only 12 items discriminated fluoxetine 
from placebo. Discrimination between the two antidepres-
sants was maximal in the area of negative self-perception 
and lack of motivation towards action. In the subgroup of 
91 patients in remission (Hamilton Depression Rating Scale 
[HAMD] # 10) at the end of the study, the mean SASS total 
score for   reboxetine was also significantly higher than that of 
both fluoxetine and placebo (P , 0.05). A direct comparison 
of reboxetine and fluoxetine showed that 14 SASS items 
showed a significantly greater improvement with reboxetine 
treatment.
Another study36 compared the effects of reboxetine 
8–10 mg/day and fluoxetine 20–40 mg/day over eight weeks 
in 168 patients with acute major depressive episode. Both 
antidepressants improved scores on the HAMD to a similar 
extent. In patients treated for at least four weeks, the mean 
SASS total score was improved by 42.4% in the reboxetine 
group and 33.3% in the fluoxetine group, although this 
difference was not significantly different. In patients who 
achieved remission (HAMD # 10), the mean SASS total 
score improvement in the reboxetine group was 43.5% 
compared with 29.37% in the fluoxetine group (P , 0.05). 
The quality of remission, in terms of social adjustment, was 
better in the reboxetine group, with greater improvement 
on almost all individual items compared with the fluoxetine 
group, and statistically significant differences for “interest 
in hobbies” (P = 0.02), “gregariousness” (P = 0.01), “dif-
ficulties in coping with resources” (P = 0.03), and “control 
of surroundings” (P = 0.04).
These studies suggest that noradrenergic agents, such 
as reboxetine, may be particularly effective in improving 
  negative self-perception and lack of motivation, leading to a 
better quality of remission in terms of social functioning.37
A meta-analysis of nine studies (n = 2641 patients) of 
durations ranging over 8–24 weeks comparing reboxetine with 
fluoxetine, paroxetine, and citalopram38 showed comparable 
antidepressant response rates between reboxetine and the 
grouped SSRIs. However, the analysis failed to show a signifi-
cant difference in improvement in psychosocial functioning, 
as measured by the SASS, between the reboxetine and SSRI 
groups, although the SASS was not used in all studies.
Effects of serotonin norepinephrine 
reuptake inhibitors on social 
adaptation
If improved social adaptation is related to increased noradren-
ergic activity, then SNRIs should be particularly effective in 
reducing social dysfunction in depressed patients. However, 
to date, the effects of SNRIs on social adaptation in depressed 
patients have been measured in only a few studies. There have 
been no studies using the SASS or another social adaptation 
scale comparing SNRIs and SSRIs.
venlafaxine
A small study compared treatment with venlafaxine and 
amitriptyline on social functioning in depressed patients,39 
although this study used the Self-Report Social Adjustment 
Scale (SAS-SR) and not the SASS. Twenty-eight outpatients, 
with recurrent or single major depressive episodes, took 
part in a double-blind, eight-week trial with amitriptyline 
or venlafaxine (both drugs administered at doses up to 
150 mg/day), and were assessed by the SAS-SR at baseline 
and at the end of treatment. Both drugs showed comparable 
efficacy for improving depressive symptoms. Amitriptyline-
treated patients showed a significant (P , 0.005) overall 
improved SAS-SR score and a significant improvement in 
several subscales (work P = 0.005; leisure time P = 0.006; 
economic situation P , 0.05). However, venlafaxine-treated 
patients showed a significantly greater improvement in social 
adjustment on the SAS-SR than those treated with amitrip-
tyline (P , 0.05). Venlafaxine-treated patients showed a 
significant (P , 0.001) overall improved SAS-SR score and 
a significant improvement in all subscales except economic 
situation (work P , 0.001; leisure time, extended family, 
marital, parental, family unit P , 0.05). In addition, only 
venlafaxine-treated patients reached SAS-SR values in the 
range for normal subjects. This difference may reflect the 
greater noradrenergic component of venlafaxine’s mechanism 
of action.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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In an open-label naturalistic case study, five patients with 
treatment-resistant severe major depressive disorder were 
treated with high-dose (450–600 mg/day) venlafaxine XL.40 
At the end of the 24-week study, four of the five patients had 
a greater than 50% decrease in HAMD scores. For two of 
these patients, SASS scores were within the normal range 
at the end of the study.
Duloxetine
The only study of duloxetine using the SASS41 is a small 
study in seasonal affective disorder (SAD). Twenty-six 
patients suffering from SAD were treated in an open-label 
design with duloxetine (60–120 mg/day) for eight weeks. 
Duloxetine treatment led to a significant improvement 
(P , 0.001) of HAMD (SAD version) and SASS scores. 
Work days lost due to illness and days with reduced produc-
tivity were also significantly fewer (P , 0.001) at the end of 
treatment. These preliminary results suggest that duloxetine 
may improve the negative social consequences of SAD.
Milnacipran
Milnacipran is the most balanced of the SNRI in terms of its 
selectivity for the inhibition of NE and 5-HT reuptake and 
has the most noradrenergic potency ratio of all the SNRIs.42 
As such, its effects on social adaptation would be expected 
to be particularly marked. Two recent studies have examined 
the effect of milnacipran on social adaptation as measured by 
the SASS. Both have been published exclusively in Japanese 
and will therefore be presented here in some detail because 
they are not otherwise available to most of the scientific 
community.
One study43 investigated 45 patients (28 men and 
17 women, of mean age 46.2 years) diagnosed with major 
depressive disorder. Milnacipran was administered at 
50 to 100 mg/day. The initial mean dose was 57.1 mg/day. 
The mean dose at the end of the eight-week study was 
83.7 mg/day. HAMD, Beck Depression Inventory (BDI), 
and SASS were assessed at baseline and after 2, 4, 6, and 8 
weeks treatment. Baseline scores were: HAMD 22.2; BDI 
26.7; and SASS 24.4.
Significant improvements (P , 0.05) in the HAMD 
and BDI were seen after two weeks and in the SASS after 
four weeks. After eight weeks of treatment, 51.1% patients 
were in remission on HAMD (remission , 7) and 42.2% 
on SASS (remission . 35, Figure 2). Patients who did not 
respond to treatment (,50% reduction of baseline HAMD 
score after eight weeks) had no significant improvement in 
their SASS score at endpoint. The authors found a significant 
negative correlation between the reduction in HAMD score 
from baseline to endpoint (∆HAMD) and the increase in 
SASS score from baseline to endpoint (∆SASS, r = 0.598; 
P , 0.01).
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A second study investigated the effect of milnacipran 
treatment on the evolution of social adaptation using the 
SASS in parallel with the HAMD and the Zung Self-
  evaluation Depressive Rating Scale (SDS).44 A cohort of 
113 patients (20–65 years), employees, or   homemakers who 
  carried out home tasks, diagnosed with major   depressive 
episode   according to the DSM-IV criteria, was recruited. 
  Milnacipran was administered at a starting dose of 
25–50 mg/day, increasing if necessary to 100 mg/day after 
1–2 weeks and then continuing at this dose for 8–12 weeks. 
After 12 weeks the average dose was 85.4 mg/day.
Twelve of the 113 enrolled patients did not return after 
the first visit and were therefore excluded from the analysis. 
Five patients withdrew due to adverse effects within the 
first two weeks. Efficacy analysis, carried out on a total of 
101 patients using the last observation carried forward tech-
nique, showed a significant improvement for all three scales 
at endpoint (P , 0.01). Mean HAMD and SDS scores were 
significantly reduced (P , 0.01) after two weeks whereas the 
SASS was only significantly increased (P , 0.01) from four 
weeks (Figure 3). After eight weeks, 67.4% patients were 
classified as responders ($50% reduction of the baseline 
HAMD score), 43.0% were in remission (HAMD # 7), and 
33.3% patients had remission on SASS ($35 points).
After four weeks, the dose had been increased to 
100 mg/day in 23 patients, with 63 patients remaining at 
doses of less than 100 mg/day. Patients in the high-dose 
group had significantly greater improvements on the HAMD 
and SASS scales (Table 2).
Although a third of patients achieved remission on the 
SASS after 12 weeks, the mean SASS score after 12 weeks 
(31.3 ± 3.7) was still below the remission level (.35). There 
was a significant negative correlation between ∆SASS (base-
line to endpoint difference) and ∆HAMD (-0.39, P , 0.01) 
although the correlation was considerably weaker than 
between the two depression scales (∆HAMD and ∆SDS; 
0.74, P , 0.01).
Both of these Japanese studies showed a significant 
improvement on the SASS scale by four weeks of treatment, 
whereas a significant improvement on depression scales, ie, 
HAMD, BDI, and SDS, occurred by two weeks. Although 
both studies showed a significant negative correlation 
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between changes in the SASS and changes in the HAMD, 
the correlation was weaker than between the two depression 
rating scales.
These results suggest that social adaptation, as measured 
by the SASS, may be more difficult and slower to achieve than 
improvement in classical depressive symptoms. In addition, 
although there is a correlation between SASS   improvement 
and HAMD improvement, and the dispersion is greater than 
when comparing two depression scales,   suggesting that in 
spite of certain similarities, the scales do not measure the 
same underlying functions. Finally, higher doses appear to 
favor a more rapid recovery from social dysfunction and thus 
a rapid return to productivity in the workplace and an overall 
improved quality of life.
We have found mention of only a single study comparing 
improvement of social adaptation between SNRIs and SSRIs. 
A study presented orally in Japanese46 and cited in a review47 
compared depressed patients (n = 15 per group) treated by 
milnacipran (mean dose 83 mg/day) or paroxetine (mean dose 
35 mg/day). From the data presented47 (Figure 4), milnacipran 
treatment appears to result in a greater number of patients 
with social remission than paroxetine. Not surprisingly, in 
view of the small study population, the difference was not 
significant. This difference is consistent with that found in 
some studies between the selective NE reuptake inhibitor, 
reboxetine and the SSRI, fluoxetine (see above).34–36
Conclusions
Social dysfunction is a common feature in depressed 
patients and has important implications for quality of life. 
Because the level of social functioning may be significant 
in determining the course of the illness and risk of relapse,37 
this aspect of depression merits particular attention. The 
role of antidepressants in alleviating social impairment 
is poorly studied, and it is unknown whether antidepres-
sants act directly to affect mechanisms that mediate social 
functioning, or indirectly via clinical improvement of the 
core symptoms of depression. The effects of depression 
Table 2 Change in scores on the different rating scales from 
baseline  to  endpoint  for  high-dose  and  low-dose  milnacipran 
groups 
∆HAMD ∆SDS ∆SASS
Low-dose group* -12.3 ± 8.2 -13.8 ± 10.9 4.0 ± 7.3
High-dose group**  -14.5 ± 9.5 -17.4 ± 12.0 9.8 ± 8.1
P 0.011 0.163 0.049
Notes: *Patients whose dose of milnacipran had not been raised to 100 mg/day by 
the end of week 4 (n = 63); **Patients whose dose of milnacipran had been raised 
to 100 mg/day or more by the end of week 4 (n = 23); P = difference between high 
and low groups. 
Abbreviations: SD, standard deviation; ∆HAMD, mean (±SD) difference in scores 
on the Hamilton Depression Rating Scale from baseline to endpoint; ∆SDS, mean 
(±SD) difference in scores on the Self-evaluation Depressive Rating scale from baseline 
to endpoint; ∆SASS, mean (±SD) difference in scores on the Social Adaptation Self-
evaluation Scale from baseline to endpoint. Developed from data.41
0
0 123 456 7 89
20
40
60
80
%
 
p
a
t
i
e
n
t
s
 
i
n
 
r
e
m
i
s
s
i
o
n
Milnacipran (n = 15)
Paroxetine (n = 15)
P = 0.09
Weeks of treatment
Baseline
Figure 4 Social adaptation for patients in remission during treatment with milnacipran and paroxetine. Remission for social adaptation defined as Social Adaptation Self-
evaluation Scale . 35. Milnacipran was administered at a mean dose of 83 mg/day (n = 15) and paroxetine at 35 mg/day (n = 15). Drawn from data.46Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
654
Briley and Moret
on social functioning fit into the monoamine hypothesis of 
depression through the   improvement of symptoms related to 
noradrenergic function.21,22,45 The important implication of 
NE in social dysfunction in depression is supported by studies 
with antidepressants acting specifically on the noradrenergic 
system, such as reboxetine, both in healthy volunteers and 
in depressed patients.
There is a suggestion that antidepressants activating nora-
drenergic neurotransmission may improve social functioning 
more rapidly and/or to a greater extent than those acting 
exclusively on serotonergic function. If this is indeed true, 
SNRIs would also be expected to be particularly effective 
in improving social functioning.
The studies currently available are all small and many of 
them are not comparative. This is a clear limitation of support 
for the hypothesis. From these preliminary data, SNRIs do 
appear to improve social functioning, with possibly a slower 
time course than for the improvement of depressive symp-
toms. Although there is a first indication that milnacipran 
may possibly produce a greater effect on social adaptation 
than the SSRI, paroxetine, this interesting question is still 
open. We hope that this review will stimulate the curiosity 
of investigators and encourage then to include the SASS in 
future trials comparing SNRIs and SSRIs.
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